

To

Dated 27.05.2026

BSE Limited 25th Floor Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
--	--

Sub: Annual Secretarial Compliance Report for the year ended March 31, 2026

Dear Sir,

This is with reference to submission of Secretarial Compliance Report under regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for year ended March 31, 2026 and in continuation to the SEBI Circular no SEBI/HO/CFD/CMD1/P/CIR/2021/556 dated April 29, 2021, please find attached Annual Secretarial Compliance Report as issued by M/s. AMJ & Associates, Practicing Company Secretaries for the financial year ended March-2026.

You are requested to take the same on record.

Thanking You

Yours truly,

For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS44157

Encl: As Above.

**SECRETARIAL COMPLIANCE REPORT OF
MEDICAMEN BIOTECH LIMITED
(CIN: L74899DL1993PLC056594)
FOR THE YEAR ENDED 31ST MARCH, 2026**

We have conducted the review of the compliance of the applicable statutory provisions and the adherence to good corporate practices by **MEDICAMEN BIOTECH LIMITED** (hereinafter referred as 'the listed entity'), having its Registered Office at **1506, Chiranjiv Tower, 43, Nehru Place New Delhi - 110019**, Secretarial Review was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the listed entity's books, papers, minutes books, forms and returns filed and other records maintained by the listed entity and also the information provided by the listed entity, its officers, agents and authorized representatives during the conduct of Secretarial Review, we hereby report that in our opinion, the listed entity has, during the review period covering the financial year ended on **31st March, 2026**, complied with the statutory provisions listed hereunder and also that the listed entity has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We, **AMJ & Associates**, Practicing Company Secretary have examined:

- a. all the documents and records made available to us and explanation provided by **MEDICAMEN BIOTECH LIMITED**("the listed entity"),
- b. the filings/ submissions made by the listed entity to the stock exchanges,
- c. website of the listed entity,
- d. any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended **31st March, 2026**("Review Period") in respect of compliance with the provisions of:

- a. the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- b. the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- c. Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)Regulations, 2015;

- d. Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- e. Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- f. Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **(Not applicable to the Company during the Review period)**
- g. Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity Shares) Regulations, 2021; **(Not applicable to the Company during the Review period)**
- h. Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **(Not applicable to the Company during the Review period)**
- i. Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- j. Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **(Not applicable to the Company during the Review period)**
- k. Securities and Exchange Board of India (Depository Participant) Regulations, 2018;
- l. Securities and Exchange Board of India {KYC (Know Your Client) Registration Agency} Regulations, 2011.
- m. Securities and Exchange Board of India (Investor Protection and Education Fund) Regulations, 2009.
- n. Securities and Exchange Board of India (Prohibition of Fraudulent and Unfair Trade Practices Relating To Securities Market) Regulations, 2003
- o. Securities and exchange board of India (Procedure for Board Meetings) Regulations, 2001
- p. Securities and Exchange Board of India (Employees' Service) Regulations, 2001
- q. Securities and Exchange Board of India (Custodian) Regulations, 1996
- r. Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993.

and circulars/ guidelines issued thereunder; and based on the above examination, We hereby report that, during the review period:

- (a). The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below: –

Sr. No.	Compliance Requirement (Regulations/circulars/guidelines including specific clause)	Regulation/Circular No.	Deviations	Action Taken by	Type of Action	Details of Violation	Fine Amount	Observations/Remarks of the Practicing Company Secretary	Management Response	Remarks
1.	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

(b) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No.	Observations / Remarks Of the Practicing Company Secretary in the previous report(s) (PCS)	Observations made in the secretarial compliance report for the year ended 31.03.2025	Compliance Requirement (Regulations/circulars/guidelines including specific clause)	Details of violation / deviations and actions taken / penalty imposed, if any, on the listed entity	Remedial actions, if any, taken by the listed entity	Comments of the PCS on the actions taken by the listed entity
1.	Regulation-26A-Delay in filling the Vacancy in the office of Chief Financial Officer (CFO)	The Vacancy of Chief Financial Officer (CFO) was not filed within three months from the date of vacancy.	The Vacancy of Chief Financial Officer (CFO) should be filed within three months from the date of vacancy.	The Vacancy of Chief Financial Officer (CFO) was not filed within three months from the date of vacancy.	The Vacancy was filed on 11.02.2025 by appointment of CFO	The Vacancy was filed on 11.02.2025 by appointment of CFO

I. We hereby report that, during the Review Period the compliance status of the listed entity with the following requirements:

Sr. No.	Particulars	Compliance Status (Yes/No/NA)	Observations/Remarks by PCS*
1	<u>Secretarial Standards:</u> The compliances of the listed entity are in accordance with the applicable Secretarial Standards (SS) issued by the Institute of Company Secretaries India (ICSI).	YES	-
2	<u>Adoption and timely Updation of the Policies:</u> • All applicable policies under SEBI Regulations are adopted with the approval of board of directors of the listed entities.	YES	-

	<ul style="list-style-type: none"> All the policies are in conformity with SEBI Regulations and has been reviewed & timely updated as per the regulations/circulars/guidelines issued by SEBI. 	YES	-
3	<p><u>Maintenance and disclosures on Website:</u></p> <ul style="list-style-type: none"> The Listed entity is maintaining a functional website. Timely dissemination of the documents/information under a separate section on the website. Web-links provided in annual corporate governance reports under Regulation 27(2) are accurate and specific which re-directs to the relevant document(s)/ section of the website. 	YES YES YES	- - -
4	<p><u>Disqualification of Director:</u></p> <p>None of the Director of the Company are disqualified under Section 164 of Companies Act, 2013 as confirmed by listed entity.</p>	YES	-
5	<p><u>Details related to Subsidiaries of listed entities has been examined w.r.t.:</u></p> <p>a) Identification of material subsidiary companies.</p> <p>b) Disclosure requirements of material as well as other subsidiaries.</p>	YES YES	At the end of the year under review, the Company had the 2 (Two) subsidiaries namely Opal Pharmaceuticals Pty Ltd. and Medicamen Life Sciences Private Limited. However No Material Subsidiary was reported by the Company.
6	<p><u>Preservation of Documents:</u></p> <p>The listed entity is preserving and maintaining records as prescribed under SEBI Regulations and disposal of records as per Policy of Preservation of Documents and Archival policy prescribed under SEBI LODR Regulations, 2015.</p>	YES	-
7	<p><u>Performance Evaluation:</u></p> <p>The listed entity has conducted performance evaluation of the Board, Independent Directors and the Committees at the start of every financial year as prescribed in SEBI Regulations.</p>	YES	-
8	<p><u>Related Party Transactions:</u></p> <p>(a) The listed entity has obtained prior approval of Audit Committee for all Related party transactions</p> <p>(b) In case no prior approval obtained, the listed entity shall provide detailed reasons along with</p>	YES NA	- Please refer point no. 8(a)

	confirmation whether the transactions were subsequently approved/ ratified/rejected by the Audit committee		
9	Disclosure of events or information: The listed entity has provided all the required disclosure(s) under Regulation 30 along with Schedule III of SEBI LODR Regulations, 2015 within the time limits prescribed thereunder.	YES	-
10	Prohibition of Insider Trading: The listed entity is in compliance with Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015	YES	-
11	Actions taken by SEBI or Stock Exchange(s), if any: No Actions taken against the listed entity/ its promoters/ directors/ subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under SEBI Regulations and circulars/ guidelines issued thereunder (or) The actions taken against the listed entity/ its promoters/ directors/ subsidiaries either by SEBI or by Stock Exchanges are specified in the last column.	YES	Cautionary letter received from National Stock Exchange of India Ltd. (NSE) on 27 th January 2026 for observation reported by Secretarial Auditor in Secretarial Compliance Report submitted for financial year ended 31 st March, 2025
12	Resignation of statutory auditors from the listed entity or its material subsidiaries: In case of resignation of statutory auditor from the listed entity or any of its material subsidiaries during the financial year, the listed entity and / or its material subsidiary(ies) has / have complied with paragraph 6.1 and 6.2 of section V-D of chapter V of the Master Circular on compliance with the provisions of the LODR Regulations by listed entities.	NA	No Such Event has occurred during the financial year under review.
13	Additional Non-compliances, if any: No any additional non-compliance observed for all SEBI regulation/ circular/guidance note etc. except as reported above.	YES	-

We further, report that the disclosure requirements of Employee Benefit Scheme Documents in terms of regulation 46(2) (za) of LODR Regulations are **Not Applicable** to the listed entity.



AMJ & ASSOCIATES

Company Secretaries

F-2, Plot No. 299, Sector-4,
Vaishali, Ghaziabad-201010
Ph. 0120-4138598, 9811593878
manojfcs@gmail.com
www.amjassociates.in

Assumptions & Limitation of scope and Review:

1. Compliance of the applicable laws and ensuring the authenticity of documents and information furnished, are the responsibilities of the management of the listed entity.
2. Our responsibility is to report based upon our examination of relevant documents and information. This is neither an audit nor an expression of opinion.
3. We have not verified the correctness and appropriateness of financial Records and Books of Accounts of the listed entity.
4. This Report is solely for the intended purpose of compliance in terms of Regulation 24A (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is neither an assurance as to the future viability of the listed entity nor of the efficacy or effectiveness with which the management has conducted the affairs of the listed entity.
5. It is the responsibility of the Company's management to maintain records and establish appropriate systems for Ensuring compliance with applicable SEBI Regulations, circulars, and guidelines issued from time to time and to ensure the adequacy and operational effectiveness of such systems.
6. Our examination was limited to the verification of procedure on random test basis and the verification was done on random test basis to ensure that correct facts are reflected in secretarial records.

Place: Ghaziabad
Date: 27.05.2026

For AMJ & Associates
Company Secretaries
PR Certificate No.: 1640/2021

Manoj
Kumar
Jain

Digitally signed
by Manoj Kumar
Jain
Date: 2026.05.27
12:38:47 +05'30'

Manoj Kumar Jain
(Proprietor)
FCS No.: 5832, C.P. No.: 5629
UDIN: F005832H000498918